This is a list of all the questions and their associated study carrel identifiers. One can learn a lot of the "aboutness" of a text simply by reading the questions.
| identifier | question |
|---|---|
| cord-001322-7xmxcm35 | when does it happen, and do systemic inflammatory response syndrome criteria help predict course? |
| cord-026653-094bk0t0 | The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose- α-1,3-galactose Alpha- Gal in therapeutics: more relevant than thought? |
| cord-253502-v2hh3w3r | Ribavirin inhibits viral- induced macrophage production of TNF, IL-1, the procoagulant fgl 2 prothrombinase and preserves Th 1 cytokine production but inhibits Th 2 cytokine response Antiviral treatment of SARS: can we draw any conclusions? |
| cord-017758-zfudssm9 | Emerging hemorrhagic fever in China caused by a novel bunyavirus SFTSV Characterization of severe fever with thrombocytopenia syndrome in rural regions of Zhejiang A study of seroprevalence and rates of asymptomatic viremia of severe fever with thrombocytopenia syndrome virus among Chinese blood donors Systemic review of severe fever with thrombocytopenia syndrome: virology, epidemiology, and clinical characteristics Seroprevalence of antibodies against SFTS virus infection in farmers and animals Acute thrombocytopenia, leucopenia, and multiorgan dysfunction: the first case of SFTS Bunyavirus outside of China? |
| cord-007786-cu831tl7 | Recent advances in dengue pathogenesis and clinical management Corticosteroids for treating dengue shock syndrome Effects of short- course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebocontrolled trial Corticosteroids for dengue- why do n't they work? |
| cord-258307-nsdhvc8w | Avian influenza: a new pandemic threat? |
| cord-275506-3t5gf66c | The trinity of COVID-19: immunity, inflammation and intervention Endothelial cell infection and endotheliitis in COVID-19 COVID-19 and its implications for thrombosis and anticoagulation n COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia? |
| cord-286799-q9p5kg65 | Can some routine clinical characteristics or/ and laboratory measurements( or their combination) predict the occurrence of severe cases? |
| cord-275154-vwnpred5 | in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? |
| cord-275154-vwnpred5 | lessons from the virus for successful vaccine design Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge Critical role of IL-17RA in immunopathology of influenza infection Confronting an influenza pandemic with inexpensive generic agents: can it be done? |
| cord-277217-jh4qmoso | goal A multifaceted intervention to implement guidelines and improve admission paediatric care in Kenyan district hospitals: a cluster randomised trial Improved triage and emergency care for children reduces inpatient mortality in a resource- constrained setting Development and implementation of a national programme for the management of severe and very severe pneumonia in children in Malawi Community case management of pneumonia: at a tipping point? |
| cord-277217-jh4qmoso | international comparisons in critical care-lessons learned The reality of pediatric emergency mass critical care in the developing world Pandemic H1N1 2009: are we comparing apples with oranges? |
| cord-278477-9a7gmzz3 | In; Ho Lee, Dae; Jung, Jaehun title: Impact of obesity, fasting plasma glucose level, blood pressure, and renal function on the severity of COVID-19: a matter of sexual dimorphism? |
| cord-278477-9a7gmzz3 | Meta- analysis Obesity aggravates COVID-19: a systematic review and metaanalysis Obesity and Outcomes in COVID-19: When an Epidemic and Pandemic Collide Arterial hypertension and risk of death in patients with COVID-19 infection: Systematic review and meta- analysis Patients with arterial hypertension and COVID-19 are at higher risk of ICU admission Association of hypertension, diabetes, stroke, cancer, kidney disease, and high- cholesterol with COVID-19 disease severity and fatality: A systematic review COVID-19 and arterial hypertension: Hypothesis or evidence? |
| cord-300559-vuuxthx2 | Impaired albumin function: a novel potential indicator for liver function damage? |
| cord-286843-8qh1pblc | The immunology of influenza virusassociated bacterial pneumonia Integrated clinical, pathologic, Virologic, and transcriptomic analysis of H5N1 influenza virus- induced viral pneumonia in the rhesus macaque Kinetics of coinfection with influenza a virus and Streptococcus pneumoniae Etiology of severe communityacquired pneumonia during the 2013 hajj- part of the MERS- CoV surveillance program Clinical and molecular characterization of rhinoviruses a, B, and C in adult patients with pneumonia Human rhinoviruses and severe respiratory infections: is it possible to identify at- risk patients early? |
| cord-286843-8qh1pblc | The past decade in bench research into pulmonary infectious diseases: what do clinicians need to know? |
| cord-002757-upwe0cpj | : can we retain the clinical use of mold- active antifungal azoles? |
| cord-002757-upwe0cpj | Contribution of Working Groups I, II and III to the Fifth Assessment Report of the Intergovernmental Panel on Climate Change Impact of climate change in the epidemiology of vector- borne diseases in domestic carnivores Impact of climate change on human infectious diseases: empirical evidence and human adaptation Climate change and health: global to local influences on disease risk Climate change and mosquito- borne disease Climate of origin affects tick( Ixodes ricinus) host- seeking behavior in response to temperature: implications for resilience to climate change? |
| cord-002757-upwe0cpj | The burden of co- infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub- saharan Africa Is there an interaction between human immunodeficiency virus and Plasmodium falciparum? |
| cord-253077-61fmul8c | ( COVID-19): A Review Effects of chloroquine on viral infections: an old drug against today's diseases? |
| cord-253077-61fmul8c | :( 1) what is the contribution of T cells to initial virus control and tissue damage in the context of COVID-19, and( 2) how do memory T cells established thereafter contribute to protective immunity upon re- infection? |
| cord-253077-61fmul8c | Cytoplasmic Origin SARS- CoV-2 is sensitive to type I interferon pretreatment Prediction and Evolution of B Cell Epitopes of Surface Protein in SARS- CoV-2 Serology characteristics of SARS- CoV-2 infection since the exposure and post symptoms onset Quantifying treatment effects of hydroxychloroquine and azithromycin for COVID-19: a secondary analysis of an open label non- randomized clinical trial Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Adjuvant corticosteroid therapy for critically ill patients with COVID-19( medRxiv) Meta- Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment? |
| cord-260238-2p209g2p | An influenza epicentre? |
| cord-260238-2p209g2p | Severe acute respiratory syndrome- related coronavirus is inhibited by interferon- α The antiviral effect of interferon- β against SARS coronavirus is not mediated by MxA protein Old drugs as lead compounds for a new disease? |
| cord-260238-2p209g2p | What does the peripheral blood tell you in SARS? |
| cord-325170-50oy9qqy | : What is the role of radiologists? |
| cord-324840-ug5a9wx6 | An evolutionary advantage of low MBL production genotypes? |
| cord-305223-go75cs6r | Emerg Microbes Infect Viral pneumonia in severe respiratory failure Clinical management of severe acute respiratory infection when novel coronavirus( nCoV)infection is suspected: interim guidance Hypoalbuminemia in acute illness: is there a rationale for intervention? |
| cord-030369-4dn02a35 | If the strict definition of acute and subacute liver failure as"no past history of liver disease"is executed, how to name the patients who had a history of chronic liver disease( caused by HBV from mother to child transmission in China)? |
| cord-030369-4dn02a35 | When should"I"consider a new hepatitis B virus genotype? |
| cord-030369-4dn02a35 | is tenofovir the answer? |
| cord-305583-p2jp5fiq | Antimicrob Agents Chemother Plasmodium vivax Chesson strain Treatment of Plasmodium vivax malariaetime for a change? |
| cord-305583-p2jp5fiq | Artemisinin- based combination therapy for treating uncomplicated Plasmodium vivax malaria Plasmodium vivax resistance to chloroquine? |
| cord-297323-l3f12hg4 | A Multibasic Cleavage Site in the Spike Protein of SARS- CoV-2 Is Essential for Infection of Human Lung Cells Clinical and immunologic features in severe and moderate Coronavirus Disease Asymptomatic carriage and transmission of SARS- CoV-2: What do we know? |
| cord-297323-l3f12hg4 | Reduced dynamic range of antiviral innate immune responses in aging Oxidative stress, inflamm- aging and immunosenescence Genomewide Association Study of Severe Covid-19 with Respiratory Failure Metabolic Alterations in Aging Macrophages: Ingredients for Inflammaging? |
| cord-297323-l3f12hg4 | Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection COVID-19 as a STING disorder with delayed over- secretion of interferon- beta Activated STING in a Vascular and Pulmonary Syndrome Dampened STING- Dependent Interferon Activation in Bats Pathogenic role of HMGB1 in SARS? |
| cord-032181-gmcugd8h | : What do we really know? |
| cord-032181-gmcugd8h | The pathophysiology of trauma- induced coagulopathy Laboratory evidence of hyperfibrinolysis in association with low PAI-1 activity Interventional algorithms for the control of coagulopathic bleeding in surgical, trauma, and postpartum settings: recommendations from the Share Network Group Hyperfibrinolysis and the risk of hemorrhage in stable cirrhotic patients Does negative heparin- platelet factor 4 enzymelinked immunosorbent assay effectively exclude heparin- induced thrombocytopenia? |
| cord-032181-gmcugd8h | The role of antioxidants and zinc in minimal hepatic encephalopathy: a randomized trial Tranilast reduces serum IL-6 and IL-13 and protects against thioacetamide- induced acute liver injury and hepatic encephalopathy Is it worth removing albumin- bound substances in hepatic encephalopathy? |
| cord-016057-efc6msf4 | HIV and malaria, do they interact? |
| cord-016057-efc6msf4 | The anaemia of falciparum malaria Do patients with cerebral malaria have cerebral oedema? |
| cord-016057-efc6msf4 | What is the future of exchange transfusion in severe malaria? |
| cord-016057-efc6msf4 | Why do some African children develop severe malaria? |
| cord-337137-0ey40gzw | How the SARS coronavirus causes disease: host or organism? |
| cord-017870-5fu4uswq | A double- blind, placebo- controlled trial Do patients with cerebral malaria have cerebral oedema? |
| cord-017870-5fu4uswq | Are we losing artemisinin combination therapy already? |
| cord-017870-5fu4uswq | Endotoxin Cerebral malaria: mediators, mechanical obstruction or more? |
| cord-017870-5fu4uswq | The malaria vaccine: anti- parasite or anti- disease? |
| cord-017870-5fu4uswq | What's new in malaria control? |
| cord-347058-kejcwlng | non- severe COVID-19 patients, a systematic review and meta- analysis Prognostic significance of neutrophil- tolymphocyte ratio in patients with sepsis: a prospective observational study Immune- epidemiological parameters of the novel coronavirusa perspective Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study Covid-19 pandemic and the skin- What should dermatologists know? |
| cord-285557-my16g91c | A major outbreak of severe acute respiratory syndrome in Hong Kong Profile of specific antibodies to the SARS- associated coronavirus Clinical observation on 103 patients of severe acute respiratory syndrome treated by integrative traditional Chinese and Western Medicine Transmission dynamics and control of severe acute respiratory syndrome Medicinal herbs for hepatitis C virus infection Viral zoonoses- a threat under control? |
| cord-285557-my16g91c | Koch's postulates fulfilled for SARS virus Critically ill patients with severe acute respiratory syndrome SARS genome patent: symptom or disease? |
| cord-285557-my16g91c | Ribavirin in the treatment of SARS: a new trick for an old drug? |
| cord-285557-my16g91c | The big question now: will it be back? |
| cord-316928-ivwz7jxi | Clinical characteristics of coronavirus disease 2019 in China Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Characteristics of and important lessons from the coronavirus disease 2019( COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China Renin- angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon Renin- Angiotensin system blockers Antihypertensive treatment with ACEI/ ARB of patients with COVID-19 complicated by hypertension Renin- Angiotensin- Aldosterone system inhibitors in patients with Covid-19 Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? |
| cord-316928-ivwz7jxi | Renin- angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension Antihypertensive drugs and risk of COVID-19? |
| cord-316928-ivwz7jxi | ofCOVID-19? |
| cord-302166-tah3jdw0 | COVID-19? |
| cord-302166-tah3jdw0 | Severe COVID-19 in the young and healthy: monogenic inborn errors of immunity? |
| cord-302166-tah3jdw0 | The human genetic determinism of life- threatening infectious diseases: genetic heterogeneity and physiological homogeneity? |
| cord-302166-tah3jdw0 | title: Severe COVID-19 in the young and healthy: monogenic inborn errors of immunity? |
| cord-332298-ig1j5z07 | Bronchoalveolar lavage fluid neutrophilia is associated with the severity of pulmonary lesions during equine asthma exacerbations Persistent mucus accumulation: a consequence of delayed bronchial mucous cell apoptosis in RAO- affected horses? |
| cord-332298-ig1j5z07 | Role of neutrophils in equine asthma Recurrent airway obstruction in horsesan allergic inflammation: a review Correlation between nuclear factor- κ B activity in bronchial brushing samples and lung dysfunction in an animal model of asthma Antioxidant and inflammatory responses of healthy horses and horses affected by recurrent airway obstruction to inhaled ozone Neutrophil extracellular traps in pulmonary diseases: too much of a good thing? |
| cord-332298-ig1j5z07 | can equine heaves help us better understand human asthma immunopathology and its functional consequences? |
| cord-332480-3uodkrkp | A Future H5N1 Treatment? |
| cord-332480-3uodkrkp | Intravenous immunoglobulin for infectious diseases: back to the pre- antibiotic and passive prophylaxis era? |
| cord-332480-3uodkrkp | medRxiv Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19 Intravenous immunoglobulin therapy: how does IgG modulate the immune system? |
| cord-312486-rumqopg0 | Management of patients with Crohn's Disease and Ulcerative Colitis during the coronavirus disease-2019 pandemic: results of an international meeting Factors associated with COVID-19-related death using OpenSAFELY Epigenetic dysregulation of ACE2 and interferon- regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients On the alert for cytokine storm: immunopathology in COVID-19 COVID-19-induced acute respiratory failure- an exacerbation of organ- specific autoimmunity? |
| cord-312486-rumqopg0 | What has SARS- CoV-2 revealed? |
| cord-312486-rumqopg0 | an overview The Complement System in COVID-19: Friend and Foe? |
| cord-312486-rumqopg0 | medRxiv Serum IgA, IgM, and IgG responses in COVID-19 Anti- SARS- CoV IgG response in relation to disease severity of severe acute respiratory syndrome Anti- spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS- CoV infection Antibodydependent infection of human macrophages by severe acute respiratory syndrome coronavirus Molecular mechanism for antibodydependent enhancement of coronavirus entry Clinical efficiency of intravenous immunoglobulin therapy in critical patients with COVID-19: a multicenter retrospective cohort study The potential danger of suboptimal antibody responses in COVID-19 Frequency of infection in patients with Rheumatoid Arthritis compared with controls: a population study Risk of severe herpes simplex virus infection in SLE: analysis of epidemiology and risk factors analysis in Taiwan Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? |
| cord-018764-02l423mk | As outlined in the section'Is hyperlactataemia a cause or marker of the acidosis of malaria?' |
| cord-018764-02l423mk | Possible central role of nitric oxide in conditions clinically similar to cerebral malaria Nitric oxide potently and reversibly deenergizes mitochondria at low oxygen tension Tumor necrosis factor- alpha and lipopolysaccharide enhance interferoninduced antichlamydial indoleamine dioxygenase activity independently Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN- gamma- independent mechanism Metabolites of the kynurenine pathway of tryptophan metabolism in the cerebrospinal fluid of Malawian children with malaria Cerebrospinal fluid studies in children with cerebral malaria: An excitotoxic mechanism? |
| cord-018764-02l423mk | Reevaluation of the role of cellular hypoxia and bioenergetic failure in sepsis Does tissue acidosis in sepsis indicate tissue hypoperfusion? |
| cord-018764-02l423mk | The effect of intravenous lactate on cerebral function during hypoglycaemia Lactate as a pivotal element in neuron- glia metabolic cooperation Unaccounted for anion in metabolic acidosis during severe sepsis in humans Unmeasured anions identified by the Fencl- Stewart method predict mortality better than base excess, anion gap, and lactate in patients in the pediatric intensive care unit Unidentified acids of strong prognostic significance in severe malaria Glucose homeostasis in children with falciparum malaria: precursor supply limits gluconeogenesis and glucose production Hypoglycemia as a manifestation of sepsis Hypoglycaemia is an important complication of falciparum malaria Severe falciparum malaria Intracranial pressure in childhood cerebral malaria Intracranial hypertension in Africans with cerebral malaria Prognostic significance and course of retinopathy in children with severe malaria Blood- brain barrier in falciparum malaria Breaking down the blood- brain barrier: signaling a path to cerebral malaria? |
| cord-018764-02l423mk | The injured child is resistant to multiple organ failure: a different inflammatory response? |
| cord-018764-02l423mk | where do they come from; where do they go to? |
| cord-294700-pb5k21da | : First case report Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis Ruxolitinib for the treatment of lymphoma- associated hemophagocytic lymphohistiocytosis: A cautionary tale Ruxolitinib in treatment of severe coronavirus disease 2019( COVID-19): A multicenter, single- blind, randomized controlled trial Use of Baricitinib in Patients with Moderate and Severe COVID-19 Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention Baricitinib for COVID-19: a suitable treatment? |
| cord-294700-pb5k21da | : Implications for Paediatric Syndromes? |
| cord-294700-pb5k21da | WHICH IMMUNOMODULATORY AGENTS SHOULD BE CONSIDERED? |
| cord-294700-pb5k21da | What agents, if any, are preferred if immunomodulatory therapy is considered for children with COVID-19? |
| cord-294700-pb5k21da | What criteria define the pediatric population in whom immunomodulatory therapy may be considered? |
| cord-000522-d498qj2b | Can drotrecogin alfa( activated) be used in patients on dialysis for pre- existing renal failure, a category that was specifically excluded in the PROWESS trial? |
| cord-000522-d498qj2b | Do patients require any laboratory testing before they receive drotrecogin alfa( activated)? |
| cord-000522-d498qj2b | How do severe sepsis and septic shock differ hemodynamically in the early stages compared with that classically described in the ICU? |
| cord-000522-d498qj2b | What are the most important ways in which EGDT can improve outcomes? |
| cord-000522-d498qj2b | What is the optimal dose for this intervention? |
| cord-000522-d498qj2b | What is the optimal duration for this intervention? |
| cord-000522-d498qj2b | Why was cardiovascular collapse a significant cause of death in the control group? |
| cord-334564-bqh9jkds | Evidence from a population- based eleven- year survey in Japan Is living alone"aging alone"? |
| cord-334564-bqh9jkds | If the increase in cytokine levels and the manifestation of psychiatric symptoms are related to the severity of the symptoms of SARS- CoV infection, the"cytokine storm"might also be related to the"mental health thunderstorms"seen in patients with COVID-19? |
| cord-334564-bqh9jkds | Traumatic memories, post- traumatic stress disorder and serum cortisol levels in long- term survivors of the acute respiratory distress syndrome Disrupted glucocorticoid- Immune interactions during stress response in schizophrenia Life events and high- trait reactivity together predict psychotic symptom increases in schizophrenia Increased serum interleukin-6 levels in early stages of psychosis: associations with at- risk mental states and the severity of psychotic symptoms Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population- based register study The psychological impact of quarantine and how to reduce it: rapid review of the evidence Immediate psychological responses and associated factors during the initial stage of the 2019 coronavirus disease( COVID-19) epidemic among the general population in china Living alone and depressive symptoms: the influence of gender, physical disability, and social support among Hispanic and non- Hispanic older adults Living alone and depression: the modifying role of the perceived neighborhood environment Living alone or with others and depressive symptoms, and effect modification by residential social cohesion among older adults in Japan: the JAGES longitudinal study Living arrangements and risk for late life depression: a meta- analysis of published literature Which is riskier for mental health, living alone or not participating in any social activity? |
| cord-334564-bqh9jkds | the epidemic and the challenges Anosmia and ageusia: common findings in COVID-19 patients Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China Prevalence and factors associated with depression and anxiety of hospitalized patients with COVID-19 A first case of meningitis/ encephalitis associated with SARS- Coronavirus-2 Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? |
| cord-337599-dyxfsojh | How did coronavirus start and where did it come from? |
| cord-337599-dyxfsojh | Teicoplanin potently blocks 1192 the cell entry of 2019-nCoV Teicoplanin: an alternative 1195 drug for the treatment of COVID-19? |
| cord-337599-dyxfsojh | Was it really 762 Wuhan's animal market? |
| cord-337599-dyxfsojh | Will novel virus go pandemic or be contained? |
| cord-302115-r39ser2c | Exercise, upper respiratory tract infection, and the immune system Favorable outcome of COVID19 in two patients with X- linked agammaglobulinemia A possible role for B cells in COVID-19?: |
| cord-302115-r39ser2c | How does COVID-19 kill? |
| cord-302115-r39ser2c | The species and its viruses- A statement of the Coronavirus Study Group COVID-19: what is next for public health? |
| cord-302115-r39ser2c | What makes COVID-19 pneumonia a life- threatening disease? |
| cord-302115-r39ser2c | What makes the difference? |
| cord-302115-r39ser2c | What prevents the virus from rapidly reaching the lungs and then causing severe pneumonia? |
| cord-308169-a0ft6wdy | Can asthma control be improved by understanding the patient's perspective? |
| cord-308169-a0ft6wdy | In other words,'are the pathophysiological features a consequence or an underlying cause of the disease?' |
| cord-308169-a0ft6wdy | Rhinovirus- induced wheezing in infancy- the first sign of childhood asthma? |
| cord-308169-a0ft6wdy | The link between fungi and severe asthma: a summary of the evidence Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial( FAST) study Can guideline- defined asthma control be achieved? |
| cord-308169-a0ft6wdy | Tiotropium improves lung function in Ltd patients with severe uncontrolled asthma: a randomized controlled trial Randomized trial of omalizumab( anti- IgE) for asthma in inner- city children Anti- IgE for asthma in inner- city children Dupilumab in persistent asthma with elevated eosinophil levels Against all odds: anti- IgE for intrinsic asthma? |
| cord-257344-d13at1y5 | COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? |
| cord-257344-d13at1y5 | Friend or Foe? |
| cord-257344-d13at1y5 | Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta- analysis of 53 randomized trials Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19 Insights from nanomedicine into chloroquine efficacy against COVID-19 A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus( 2019-nCoV) in vitro Hydroxychloroquine- Induced Stevens- Johnson Syndrome in COVID-19: A rare Case Report Characterizing the adverse dermatologic effects of hydroxychloroquine: a systematic review American Pharmaceutical Association Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk Arbidol: a broad- spectrum antiviral compound that blocks viral fusion Arbidol as a broad- spectrum antiviral: an update Anti- HCV, nucleotide inhibitors, repurposing against COVID-19 Ribavirin's antiviral mechanism of action: lethal mutagenesis? |
| cord-257344-d13at1y5 | Promising Supportive Therapies in Severe Cases of COVID-19? |
| cord-257344-d13at1y5 | The origin, transmission and clinical therapies on coronavirus disease 2019( COVID-19) outbreak-an update on the status COVID-19-new insights on a rapidly changing epidemic The SARS, MERS and novel coronavirus( COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? |
| cord-257344-d13at1y5 | Why and to What Extent? |
| cord-257344-d13at1y5 | the Application of Lopinavir/ Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT- PCR Patients of COVID-19 may benefit from sustained lopinavir- combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV- infected adults Should COVID-19 Concern Nephrologists? |
| cord-257344-d13at1y5 | the potential role of extracorporeal membrane oxygenation Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? |
| cord-328384-jzfr2t3p | Are the rationale for, and objectives of, the Systematic Review clearly stated? |
| cord-328384-jzfr2t3p | Publisher Full Text Are the rationale for, and objectives of, the Systematic Review clearly stated? |
| cord-328384-jzfr2t3p | Yes Are sufficient details of the methods and analysis provided to allow replication by others? |
| cord-328384-jzfr2t3p | Yes Are the conclusions drawn adequately supported by the results presented in the review? |
| cord-328384-jzfr2t3p | Yes Is the statistical analysis and its interpretation appropriate? |
| cord-350492-1s6wtj25 | A pneumonia outbreak associated with a new coronavirus of probable bat origin Are children less susceptible to COVID-19? |
| cord-350492-1s6wtj25 | Sars- coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? |
| cord-350492-1s6wtj25 | The Genotype- Tissue Expression( GTEx) pilot analysis: multitissue gene regulation in humans Macrophage activation syndrome in the era of biologic therapy Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? |
| cord-350492-1s6wtj25 | Very high serum ferritin levels are associated with increased mortality and critical care in pediatric patients Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/ sepsis/ multiple organ dysfunction syndrome/ macrophage activation syndrome: what is the treatment? |
| cord-005646-xhx9pzhj | Can HFO ce considered standard, not experimental method of therapy? |
| cord-005646-xhx9pzhj | K deficiency in earl? |
| cord-005646-xhx9pzhj | Speculation: Should not HFO be used ir pediatric patients with ARDS earlier than aggressive CMV? |
| cord-005646-xhx9pzhj | The thesis of the questionnaire was: Does the ICU syndrome occur in critical ill children in the age between three and ten, who have been intubated and/or ventilated in a PICU? |
| cord-005646-xhx9pzhj | Thunnissen t, Reinoud J.B.J. Gemke 1, Loes Veenhuizer?, Krijn Haasnoot 3, A.Johannes van Vugh0 Department of pediatrics,~Wilhelmina |
| cord-005646-xhx9pzhj | an influence of nasal mask ventilation on the REE?3.What is the nutritional state?4.What is the estimated total energy expenditure(ETE) in relation to the caloric intake? |
| cord-005646-xhx9pzhj | ~tttdy at"Ihe stale~f hematocr~ chcplm/ itic bm~ ic~ in ckil&en with 31110oN emergensy is of abviou.~!? |
| cord-286683-mettlmhz | : what decides the outcome? |
| cord-286683-mettlmhz | Could enhanced influenza and pneumococcal vaccination programs help limit the potential damage from SARS- CoV-2 to fragile health systems of southern hemisphere countries this winter? |
| cord-286683-mettlmhz | ISUOG Interim Guidance on 2019 novel coronavirus infection during pregnancy and puerperium: information for healthcare professionals Pediatric Patients With 2019 Coronavirus Disease in China Characteristics of pediatric SARS- CoV-2 infection and potential evidence for persistent fecal viral shedding Angiotensin- converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults Are children less susceptible to COVID-19? |
| cord-286683-mettlmhz | If clinically indicated:"Is it? |
| cord-286683-mettlmhz | Report of two cases& review of the literature Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records Clinical manifestations and outcome of SARS- CoV-2 infection during pregnancy Coronavirus in pregnancy and delivery: rapid review Coronavirus Disease 2019( COVID-19) and Pregnancy: What obstetricians need to know Guidelines for pregnant women with suspected SARS- CoV-2 infection Analysis of the pregnancy outcomes in pregnant women with COVID-19 in Hubei Province Novel corona virus disease( COVID-19) in pregnancy: What clinical recommendations to follow? |
| cord-286683-mettlmhz | The convalescent sera option for containing COVID-19 Drugmaker Takeda Is Working on Coronavirus Drug Breadth of concomitant immune responses prior to patient recovery: a case report of non- severe COVID-19 A Tale of Two Viruses: Does Heterologous Flavivirus Immunity Enhance Zika Disease? |
| cord-286683-mettlmhz | The role of ultrasound lung artifacts in the diagnosis of respiratory diseases Is there a role for lung ultrasound during the COVID-19 pandemic? |
| cord-299093-zp07aqpm | Do the SARS- CoV-2 proteins with more potent antagonistic immune functions increase virulence in humans compared to other HCoVs? |
| cord-299093-zp07aqpm | Question mark symbol(?) denotes |
| cord-299093-zp07aqpm | SARS- CoV-2 proteins with* denotes functional conservation with SARS- CoV Which animal(s) serves as the natural reservoir of SARS- CoV-2? |
| cord-299093-zp07aqpm | What are the correlates of immune protection for SARS- CoV2 and will they provide sterilizing immunity? |
| cord-299093-zp07aqpm | What are the underlying mechanisms contributing to an inadequate IFN response to SARS- CoV-2? |
| cord-299093-zp07aqpm | Which SARS- CoV-2 proteins antagonize innate and adaptive immune responses? |
| cord-299093-zp07aqpm | Why do some recovered patients fail to develop neutralizing antibodies? |
| cord-299093-zp07aqpm | Does active replication of SARS- CoV-2 in the upper respiratory tract contribute to enhanced transmissibility in humans? |
| cord-299093-zp07aqpm | Is intestinal SARS- CoV-2 infection a source of virus transmission? |
| cord-274802-7ioiwsd8 | : what to expect for COVID-19? |
| cord-274802-7ioiwsd8 | COVID-19 Hyperinflammation: What about Neutrophils? |
| cord-274802-7ioiwsd8 | COVID-19 pandemic and the skin: what should dermatologists know? |
| cord-274802-7ioiwsd8 | Effects of chloroquine on viral infections: An old drug against today's diseases? |
| cord-274802-7ioiwsd8 | How far the lung surfactant system gets affected during severe symptoms? |
| cord-274802-7ioiwsd8 | Lessons from atypical haemolytic uraemic syndrome Complement- mediated endothelial cell damage in immune complex vasculitis of the skin: Ultrastructurallocalization of the membrane attack complex Mannose- Binding Lectin in Severe Acute Respiratory Syndrome Coronavirus Infection Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over- activation The complement system in COVID-19: friend and foe? |
| cord-274802-7ioiwsd8 | On the adaptive immune aspects, what variations exist within population in terms of the proportion of neutralising antibodies? |
| cord-274802-7ioiwsd8 | Possible involvement of infection with human coronavirus 229E, but not NL63, in Kawasaki disease SARS- CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study Why does COVID-19 disproportionately affect older people? |
| cord-274802-7ioiwsd8 | What are the genetic contributors to susceptibility and resistance to developing COVID-19? |
| cord-274802-7ioiwsd8 | What happens during the period of latency, i.e. between being infected and showing symptoms? |
| cord-274802-7ioiwsd8 | Where and What Is the Evidence? |
| cord-274802-7ioiwsd8 | Why there are a huge population that are asymptomatic carriers? |
| cord-274802-7ioiwsd8 | observational cohort study Loss of smell and taste as symptoms of COVID-19: what does the evidence say? |
| cord-254419-qw83atrx | Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? |
| cord-254419-qw83atrx | Can we use interleukin-6( IL-6) blockade for coronavirus disease( COVID-19)-induced cytokine release syndrome( CRS)? |
| cord-254419-qw83atrx | Clinical features suggestive of macrophage activation syndrome( MAS) associated with low CD4? |
| cord-254419-qw83atrx | Cytokine and anti- cytokine interventions Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019( COVID-19) Dysregulation of immune response in patients with COVID-19 in Wuhan, China Will complement inhibition be the new target in treating COVID-19-related systemic thrombosis? |
| cord-254419-qw83atrx | Disease severity has been found to positively correlate with serum levels of TNFa, IL6, and IL10, and there was also a strong negative correlation of levels of TNFa and IL6 with the number of CD4?, CD8? |
| cord-254419-qw83atrx | Disease severity has been found to positively correlate with serum levels of TNFa, IL6, and IL10, and there was also a strong negative correlation of levels of TNFa and IL6 with the number of CD4?, CD8? |
| cord-254419-qw83atrx | In another study, lymphocyte subset analysis in COVID-19 patients showed a statistically significant lower number of CD4? |
| cord-254419-qw83atrx | In this study, patients with severe disease( 32% cases) had significantly lower CD4? |
| cord-254419-qw83atrx | In- hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19 Convalescent plasma: new evidence for an old therapeutic tool? |
| cord-254419-qw83atrx | Lupus anticoagulant is frequent in patients with Covid-19 Venous thrombosis and arteriosclerosis obliterans of lower extremities in a very severe patient with 2019 novel coronavirus disease: a case report Complement- associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19 Acute pulmonary embolism and COVID-19 pneumonia: a random association? |
| cord-254419-qw83atrx | Pulm Ther immune responses in COVID-19? |
| cord-254419-qw83atrx | T- cells, CD19? B- cells, and NK cells were found in all the patients. |
| cord-254419-qw83atrx | Why tocilizumab could be an effective treatment for severe COVID-19? High- dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019 |
| cord-254419-qw83atrx | and CD8? |
| cord-254419-qw83atrx | helper T cells, CD8? |
| cord-345371-pjbviagq | : Are we asking the right questions? |
| cord-345371-pjbviagq | An Individual Patient Data Systematic Review Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia? |
| cord-345371-pjbviagq | An Overview of Severe Acute Respiratory Syndrome- Coronavirus( SARS- CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad- Spectrum Therapeutic Strategy Old drugs as lead compounds for a new disease? |
| cord-345371-pjbviagq | Baricitinib: a chance to treat COVID-19? |
| cord-345371-pjbviagq | Bleeding and Thrombotic Manifestations of SARS- CoV2 Infection COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow- up Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? |
| cord-345371-pjbviagq | Enteric involvement of coronaviruses: is faecal- oral transmission of SARS- CoV-2 possible? |
| cord-345371-pjbviagq | Increased cardiovascular mortality in African Americans with COVID-19 Will Complement Inhibition Be the New Target in Treating COVID-19-Related Systemic Thrombosis? |
| cord-345371-pjbviagq | Inhibitory Mechanisms A Trial of Lopinavir- Ritonavir in Adults Hospitalized with Severe Covid-19 Owa Lopinavir/ ritonavir use in Covid-19 infection: is it completely non- beneficial? |
| cord-345371-pjbviagq | Is teicoplanin a complementary treatment option for COVID-19? |
| cord-345371-pjbviagq | Justified? |
| cord-345371-pjbviagq | Teicoplanin: an alternative drug for the treatment of COVID-19? |
| cord-345371-pjbviagq | The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells Cardiac arrest caused by nafamostat mesilate Three cases of treatment with Nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy Potential new treatment strategies for COVID-19: is there a role for bromhexine as add- on therapy? |
| cord-345371-pjbviagq | Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? |
| cord-345371-pjbviagq | Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors Angiotensin- I converting enzyme inhibitors as potential anti- angiogenic agents for cancer therapy Our ACE in the HOLE: Justifying the Use of Angiotensin- converting Enzyme Inhibitors as Adjuvants to Standard Chemotherapy Vascular endothelial growth factor( VEGF) in acute lung injury( ALI) and acute respiratory distress syndrome( ARDS): paradox or paradigm? |
| cord-345371-pjbviagq | Why tocilizumab could be an effective treatment for severe COVID-19? |
| cord-346539-kxnrf5g5 | -An updated interim review and lessons from SARS- CoV and MERS- CoV Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? |
| cord-346539-kxnrf5g5 | 152 pandemic? |
| cord-346539-kxnrf5g5 | 50,153 endotype is associated with severe asthma in obese patients, are obese asthmatic patients more likely to develop severe COVID-19? |
| cord-346539-kxnrf5g5 | : why might they be hazardous? |
| cord-346539-kxnrf5g5 | Advances in Diagnosis and Treatment BCG- induced trained immunity: can it offer protection against COVID-19? |
| cord-346539-kxnrf5g5 | Advice for Healthcare Professionals Treating People with Asthma( adults) in relation to COVID-19 COVID-19 Related Genes in Sputum Cells in Asthma: Relationship to Demographic Features and Corticosteroids Asthma and COVID-19: is asthma a risk factor for severe outcomes? |
| cord-346539-kxnrf5g5 | Covid-19-Navigating the Uncharted COVID-19, SARS and MERS: are they closely related? |
| cord-346539-kxnrf5g5 | Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS- CoV-2 infection is associated with disease severity and fatal outcome Immunosuppression for hyperinflammation in COVID-19: a double- edged sword? |
| cord-346539-kxnrf5g5 | IgG1(+) B- cell immunity predates IgE responses in epicutaneous sensitization to foods Laundry detergents and detergent residue after rinsing directly disrupt tight junction barrier integrity in human bronchial epithelial cells Emerging concepts and challenges in implementing the exposome paradigm in allergic diseases and asthma: a Practall document Will changes in alcohol and tobacco use be seen during the COVID-19 lockdown? |
| cord-346539-kxnrf5g5 | Is BCG vaccination affecting the spread and severity of COVID-19? |
| cord-346539-kxnrf5g5 | Is global BCG vaccination- induced trained immunity relevant to the progression of SARS- CoV-2 pandemic? |
| cord-346539-kxnrf5g5 | The Multifaceted B Cell Response in Allergen Immunotherapy COVID-19 Autopsies EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity Lung eosinophils- A novel"virus sink"that is defective in asthma? |
| cord-346539-kxnrf5g5 | The iceberg of COVID-19: are there asymptomatic cases below the surface? |
| cord-346539-kxnrf5g5 | These zoonotic beta- coronaviruses share structural and genomic similarities that are useful to patients? |
| cord-346539-kxnrf5g5 | Twelve Years after Pathogenesis of Acute Respiratory Distress Syndrome Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 Immunology of COVID-19: mechanisms, clinical outcome, diagnostics and perspectives-a report of the 1 COVID-19 pneumonia: ARDS or not? |
| cord-346539-kxnrf5g5 | What specific therapies can be suggested for ARDS? |
| cord-346539-kxnrf5g5 | Which cytokines are most elevated during CSS? |
| cord-346539-kxnrf5g5 | Will helminth co- infection modulate COVID-19 severity in endemic regions? |
| cord-346539-kxnrf5g5 | [ 277][ 278][ 279] What is the evidence supporting social distancing and face mask to prevent SARS- CoV-2 infection? |
| cord-346539-kxnrf5g5 | an urgent public health research priority Is ethnicity linked to incidence or outcomes of covid-19? |
| cord-346539-kxnrf5g5 | pandemic? |
| cord-026031-hnf5vayd | Any cleaning products used inside or outside the house within the last 48 hours? |
| cord-026031-hnf5vayd | Any construction work or renovation recently? |
| cord-026031-hnf5vayd | Any fertilizers or weed killer used in the last week? |
| cord-026031-hnf5vayd | Any mouse or rat poison in your house, yard, or garage? |
| cord-026031-hnf5vayd | Are there any abnormal postures? |
| cord-026031-hnf5vayd | Are there any characteristic odors on the breath? |
| cord-026031-hnf5vayd | Are there any other abnormal signs that you have seen? |
| cord-026031-hnf5vayd | Are there any pulse deficits or dysrhythmias auscultated? |
| cord-026031-hnf5vayd | Are there any traces of foreign material on the tongue or in the crevices of the teeth or gums? |
| cord-026031-hnf5vayd | Are there petechiae or ecchymosis on the gums or bleeding from the gumline? |
| cord-026031-hnf5vayd | Did the owner attempt any irrigation or medical techniques prior to presentation? |
| cord-026031-hnf5vayd | Did you give any medications to your animal? |
| cord-026031-hnf5vayd | Did you witness the ingestion or exposure? |
| cord-026031-hnf5vayd | Did your pet eat this morning or last night? |
| cord-026031-hnf5vayd | Do the intestinal loops feel normal, or are they fluid- filled or gas- filled? |
| cord-026031-hnf5vayd | Do you have any over- the- counter or prescription medications that your animal may have had access to? |
| cord-026031-hnf5vayd | Do you have the container with you today? |
| cord-026031-hnf5vayd | Do you hear harsh airway sounds or pulmonary crackles? |
| cord-026031-hnf5vayd | Do you observe any ptyalism or attempts to vomit? |
| cord-026031-hnf5vayd | Do you think that the signs have been the same, better, or getting worse? |
| cord-026031-hnf5vayd | Does it appear lethargic or hyperactive? |
| cord-026031-hnf5vayd | Does the animal have access to any poisonous substances? |
| cord-026031-hnf5vayd | Does your animal have access to any known toxins, or does he or she run loose unattended? |
| cord-026031-hnf5vayd | Does your animal have any ongoing or past medical problems? |
| cord-026031-hnf5vayd | Does your animal run loose outdoors unattended? |
| cord-026031-hnf5vayd | Does your pet have access to a compost pile? |
| cord-026031-hnf5vayd | Does your pet have access to neighboring properties( even for a short time)? |
| cord-026031-hnf5vayd | Does your pet run loose unattended? |
| cord-026031-hnf5vayd | For example, is the patient retaining bicarbonate( metabolic alkalosis) because of carbon dioxide retention( respiratory acidosis)? |
| cord-026031-hnf5vayd | Has it changed at all since the owner noticed the problem? |
| cord-026031-hnf5vayd | Has there been any gardening work recently? |
| cord-026031-hnf5vayd | Has there been any prior incident of ocular disease? |
| cord-026031-hnf5vayd | Has your animal been on any medications recently or currently? |
| cord-026031-hnf5vayd | Has your animal been vaccinated recently? |
| cord-026031-hnf5vayd | Has your animal had any previous or similar episodes? |
| cord-026031-hnf5vayd | Has your pet been off your property in the last 24- 48 hours? |
| cord-026031-hnf5vayd | Has your pet been to rural areas in the last week? |
| cord-026031-hnf5vayd | Has your pet had any antiflea/ tick medication within the last week?Your pet's environment Is your animal kept inside or outside of the house? |
| cord-026031-hnf5vayd | Has your pet traveled outside of your immediate geographic location? |
| cord-026031-hnf5vayd | Have any known relatives of your animal had any bleeding disorders? |
| cord-026031-hnf5vayd | Have similar signs occurred in the past? |
| cord-026031-hnf5vayd | Have the signs become better or worse since you first saw them? |
| cord-026031-hnf5vayd | Have you changed your radiator fluid or does a car leak antifreeze? |
| cord-026031-hnf5vayd | Have you fed table scraps or anything new recently? |
| cord-026031-hnf5vayd | How fast did the clinical signs develop? |
| cord-026031-hnf5vayd | How is the patient acting? |
| cord-026031-hnf5vayd | How long ago do you think that your pet was exposed to the poison? |
| cord-026031-hnf5vayd | How long ago was the exposure? |
| cord-026031-hnf5vayd | How long has the animal been acting that way? |
| cord-026031-hnf5vayd | How much did the animal consume? |
| cord-026031-hnf5vayd | How soon did other signs develop? |
| cord-026031-hnf5vayd | If so, what? |
| cord-026031-hnf5vayd | If so, when and how much did your animal consume? |
| cord-026031-hnf5vayd | If so, when? |
| cord-026031-hnf5vayd | If so, which? |
| cord-026031-hnf5vayd | Is abdominal palpation painful? |
| cord-026031-hnf5vayd | Is it a liquid concentrate, dilute spray, or solid? |
| cord-026031-hnf5vayd | Is it fast, normal, or slow? |
| cord-026031-hnf5vayd | Is it moist, dry, bubbling, or frothy, or caked with dirt? |
| cord-026031-hnf5vayd | Is it normal and pink, or dark red( injected), pale, or icteric? |
| cord-026031-hnf5vayd | Is it normal, fast, shallow, or labored? |
| cord-026031-hnf5vayd | Is it synchronous with the heart rate, or are there dropped pulses? |
| cord-026031-hnf5vayd | Is the animal ambulatory, and if so, do you observe any gait abnormalities? |
| cord-026031-hnf5vayd | Is the lens clear and is it in the normal position? |
| cord-026031-hnf5vayd | Is the ocular examination normal? |
| cord-026031-hnf5vayd | Is the pulse bounding, normal, thready, or not palpable? |
| cord-026031-hnf5vayd | Is there a P wave for every QRS, and a QRS for every P wave? |
| cord-026031-hnf5vayd | Is there a chance that your pet may have gotten into the garbage? |
| cord-026031-hnf5vayd | Is there a palpable urinary bladder? |
| cord-026031-hnf5vayd | Is there any history of trauma or known chemical irritant or exposure? |
| cord-026031-hnf5vayd | Is there any possibility of any toxin exposure? |
| cord-026031-hnf5vayd | Is there any possibility of trauma? |
| cord-026031-hnf5vayd | Is there any vomiting, diarrhea, trembling, or seizures? |
| cord-026031-hnf5vayd | Is there evidence of vomiting or diarrhea? |
| cord-026031-hnf5vayd | Is there excessive salivation? |
| cord-026031-hnf5vayd | Is there respiratory distress? |
| cord-026031-hnf5vayd | Is there urine production? |
| cord-026031-hnf5vayd | Is your animal able to walk? |
| cord-026031-hnf5vayd | Is your animal breathing or does it have respiratory difficulty? |
| cord-026031-hnf5vayd | Is your pet kept in a fenced- in yard or allowed to run loose unattended? |
| cord-026031-hnf5vayd | It is useful to phrase questions in a neutral fashion- for example,"Is such- and- such present on the premises?" |
| cord-026031-hnf5vayd | Was the substance swallowed, or is it on the animal's skin or eyes? |
| cord-026031-hnf5vayd | What clinical signs developed? |
| cord-026031-hnf5vayd | What do you hear on thoracic auscultation? |
| cord-026031-hnf5vayd | What is the animal's activity level? |
| cord-026031-hnf5vayd | What is the capillary refill time? |
| cord-026031-hnf5vayd | What is the color and consistency of the feces? |
| cord-026031-hnf5vayd | What is the color of the gums or tongue? |
| cord-026031-hnf5vayd | What is the color of the urine? |
| cord-026031-hnf5vayd | What is the mucous membrane color? |
| cord-026031-hnf5vayd | What is the name of the product? |
| cord-026031-hnf5vayd | What is the nature of the bleeding? |
| cord-026031-hnf5vayd | What is the patient's blood pressure? |
| cord-026031-hnf5vayd | What is the patient's electrocardiogram? |
| cord-026031-hnf5vayd | What is the patient's heart rate? |
| cord-026031-hnf5vayd | What is the patient's rectal temperature? |
| cord-026031-hnf5vayd | What is the patient's respiratory character? |
| cord-026031-hnf5vayd | What is the patient's respiratory rate? |
| cord-026031-hnf5vayd | What is the pupil reactivity to light? |
| cord-026031-hnf5vayd | What is the pupil size? |
| cord-026031-hnf5vayd | What is the quality of the femoral pulse? |
| cord-026031-hnf5vayd | What is the sensitivity to light or sound? |
| cord-026031-hnf5vayd | What is the substance that your animal ingested( was exposed to)? |
| cord-026031-hnf5vayd | What is your chief complaint or reason that you brought your animal in on emergency? |
| cord-026031-hnf5vayd | What other conditions have developed and what are they? |
| cord-026031-hnf5vayd | What sites are affected? |
| cord-026031-hnf5vayd | What was the first abnormal sign noticed? |
| cord-026031-hnf5vayd | When did the signs first start, or when was your animal last normal? |
| cord-026031-hnf5vayd | When did you first notice that something was wrong with your pet? |
| cord-026031-hnf5vayd | When was the animal last seen as normal? |
| cord-026031-hnf5vayd | When was the last time you noticed your pet act normally? |
| cord-026031-hnf5vayd | When was the onset of clinical signs? |
| cord-026031-hnf5vayd | When was the problem first noticed? |
| cord-026031-hnf5vayd | Where do you think it happened? |
| cord-026031-hnf5vayd | Where has your pet been in the last 24 hours? |
| cord-026031-hnf5vayd | if so, where? |
| cord-026031-hnf5vayd | or When was the last time you saw your animal act normally? |
| cord-026031-hnf5vayd | rather than"Could the dog have eaten such- and- such?" |
| cord-026031-hnf5vayd | she normally fed? |
| cord-026031-hnf5vayd | • How long has the bleeding been going on? |